GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lannett Co Inc (OTCPK:LCINQ) » Definitions » Revenue

Lannett Co (Lannett Co) Revenue : $310.7 Mil (TTM As of Mar. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Lannett Co Revenue?

Lannett Co's revenue for the three months ended in Mar. 2023 was $80.5 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2023 was $310.7 Mil. Lannett Co's Revenue per Share for the three months ended in Mar. 2023 was $7.81. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2023 was $30.31.

Warning Sign:

Lannett Co Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Lannett Co was -18.50% per year. During the past 3 years, the average Revenue per Share Growth Rate was -21.30% per year. During the past 5 years, the average Revenue per Share Growth Rate was -13.20% per year. During the past 10 years, the average Revenue per Share Growth Rate was 9.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 13 years, Lannett Co's highest 3-Year average Revenue per Share Growth Rate was 91.80% per year. The lowest was -21.30% per year. And the median was 11.50% per year.


Lannett Co Revenue Historical Data

The historical data trend for Lannett Co's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lannett Co Revenue Chart

Lannett Co Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 684.56 655.41 545.74 478.78 340.58

Lannett Co Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.36 74.19 75.08 80.89 80.51

Competitive Comparison of Lannett Co's Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Lannett Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lannett Co's Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lannett Co's Revenue distribution charts can be found below:

* The bar in red indicates where Lannett Co's Revenue falls into.



Lannett Co Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $310.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Lannett Co  (OTCPK:LCINQ) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Lannett Co Revenue Related Terms

Thank you for viewing the detailed overview of Lannett Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Lannett Co (Lannett Co) Business Description

Traded in Other Exchanges
N/A
Address
1150 Northbrook Drive, Suite 155, Trevose, PA, USA, 19053
Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.
Executives
John C Chapman director 9000 STATE ROAD, PHILADELPHIA PA 19136
Timothy C Crew officer: Chief Executive Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Jeffrey Farber officer: Secretary
Samuel H Israel officer: Chief Legal Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
John Abt officer: Vice President of Quality 9000 STATE ROAD, PHILADELPHIA PA 19136
John Kozlowski officer: Chief Operating Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
David A Drabik director 9000 STATE RD, PHILADELPHIA PA 19136
Paul Taveira director 9000 STATE ROAD, PHILADELPHIA PA 19136
Albert Iii Paonessa director 9852 NW 2ND COURT, PLANTATION FL 33324
Kevin Smith other: Vice President
Maureen Cavanaugh officer: Senior Vice President and CCOO 9000 STATE ROAD, PHILADELPHIA PA 19136
David Farber officer: Treasurer
Arthur P Bedrosian officer: President P O BOX D 1400, POMONA NY 10970